President Trump, in a recorded message on Wednesday, Oct. 7,  that went viral by media and social networks, praised the experimental drugs he was given for his treatment of the CCP Virus. The cocktail included a set of antibodies produced by the biotechnology company Regeneron.

“I was given Regeneron,” President Trump said in a video posted on his Twitter account Wednesday about his treatment at Walter Reed Medical Center.

“It was like unbelievable. I felt good immediately. I felt as good three days ago as I do now,” he added in the message. 

President Trump promised to do everything possible to get the drug approved quickly for wider use, including expressing a desire to distribute it for free.  

“I want everybody to be given the same treatment as your president, because I feel great,” President Trump said in a video from the Withe House. “I feel, like, perfect.”

The medicine that was given to President Trump, still in the experimental stage, whose scientific name is REGN-COV2, is a combination of two “monoclonal antibodies,” destined to fight SARS-CoV-2, which causes the CCP Virus. 

According to the health news media Stat, monoclonal antibodies are synthetic versions of those produced naturally by the human immune system to fight viruses.

Trials have found that the treatment was more successful in helping the recovery of patients who had not yet produced their own antiviral immune response to the coronavirus, according to the Stat report.

“The greatest benefit of the treatment was in patients who had not mounted their own effective immune response, suggesting that REGN-COV2 could provide a therapeutic substitute for the natural immune response,” Regeneron President Dr. George Yancopoulos told the Wall Street Journal.

Such patients, Yancopoulos added, were less likely to fight the virus naturally and more likely to have prolonged symptoms.

According to The Associated Press, pharmaceutical company Eli Lilly and Regeneron formally requested the Food and Drug Administration on Wednesday to allow emergency use of their experimental antibody based on early results that suggest it reduces symptoms. So far, there has been no formal response from the FDA on any particular decision.

Both companies said that if the drug were approved for administration by the FDA, they would be able to produce about 1.5 million doses immediately.